Background-An increasing number of case reports indicate potential nephrotoxicity of 5-aminosalicylic acid (5-ASA), which shares similarities with the chemical structures of both phenacetin and acetylsalicylic acid.
Abstract
Background-An increasing number of case reports indicate potential nephrotoxicity of 5-aminosalicylic acid (5-ASA), which shares similarities with the chemical structures of both phenacetin and acetylsalicylic acid. Aim-In a point prevalence study the occurrence of sensitive indices indicative of early kidney malfunction was assessed in outpatients with inflammatory bowel disease. Methods-Routine indices of kidney function (creatinine clearance, urinary protein content, pH, electrolytes, and microscopy) were investigated in 223 patients with inflammatory bowel disease as well as sensitive markers of glomerular or tubular dysfunction (microproteinuria by SDS polyacrylamide gel electrophoresis (SDS-PAGE), urinary concentrations of N-acetyl-1-D-glucosamidase, aol-microglobulin, -y-glutamyltransferase (GGT), alkaline phosphatase (AP), and albumin). Histories (17) , history of arterial hypertension (10) , chronic use of NSAID analgesics (9) , diabetes mellitus (2), pregnancy/childbirth (2), preexisting renal disease (2) . Mean duration of disease was 58.3 (range 12-132) months with a mean of 3-3 (range 1-17) acute relapses. Patients were grouped into those receiving no 5-ASA, those receiving up to 1-5 g/day, more than 1-5 but less than 3 0 g/day, and those receiving 3 0 g/day or more. In patients treated with SASP the amount of 5-ASA contained in the molecule was calculated for evaluation. No differences in disease characteristics, disease activity, or sex were seen between patients younger than than 30 and those aged 30 
Results

TREATMENTS
The Table shows 5-ASA doses taken and population characteristics of the patients with inflammatory bowel disease. Forty two per cent of patients received .3O0 g 5-ASA/day, 8% between 1-5 g/day and 3 0 g/day, and 32-6% a maximum of 1-5 g/day. The remaining (17%) patients received no 5-ASA during the two months preceding the study. Active disease was related to higher 5-ASA dosages (p<0-0001, Table) . Average duration of disease was 58-3 (range 12-132) months with an average of 3-3 (range 1-17) acute relapses. Mean duration of 5-ASA treatment was found to be 32 months.
PREVALENCE OF TUBUIAR PROTEINURIA AND RAISED URINE ALKALINE PHOSPHATASE CONCENTRATIONS
Proteinuria of tubular origin detected by SDS-PAGE is a pathological finding. In our patient population an increase in prevalence of tubular proteinuria was seen with increasing daily dose of oral 5-ASA (Fig 1, p=0 0086) . The parallel increased prevalence of raised urinary AP concentrations (>0.9 U/mmol creatinine,23 24 p=0001), which coincided highly significantly with the detection of a tubular protein pattern (p<O 000 1), indicated that the origin ofurinary proteins was most likely from the proximal tubular epithelial cells (Fig 1) Figure 3 : Point prevalence of tubular proteinuria in relation to lifetime 5-ASA intake. Point prevalence oftubular proteinuria is related to the lifetime intake of 5-ASA (p<001). Interestingly a tubular proteinuria is also seen in 9% ofpatients with inflammatory bowel disease who had never received 5-ASA in their lives. The prevalence of proteinuria with a tubular pattern in the SDS-PAGE is less than 1% in the control population (data not shown).
Discussion
Acute salicylate induced tubular nephrotoxicity has been seen in patients taking aspirin overdoses or large doses of sodium salicylate. 4 It is debated whether chronic analgesic nephropathy, which is associated with consumption of large amounts of phenacetin, is associated with salicylate intake as well.27 Moreover, 4-aminosalicylic acid (4-ASA), a structurally related molecule which has been used for the treatment of tuberculosis over many years in high systemic doses, did not generate a chronic clinical problem with drug induced nephrotoxicity.28 In high doses, however, case reports indicate acute nephrotoxicity, in particular in patients with pre-existing renal damage.28 29 The evidence for 5-ASA or sulphasalazine (SASP) induced clinically relevant renal toxicity is rare. In rats and dogs, high doses of 5-ASA (far beyond those used in human treatment) were capable of inducing acute tubular and papillary necrosis when given over six to 12 months,7 30 whereas a four week treatment did not induce any changes. 3' In this study we have assessed sensitive indices of renal function such as classification of microproteinuria by SDS-PAGE to detect early signs of tubular dysfunction. In a point prevalence study in 223 patients with inflammatory bowel disease we found an increased prevalence of tubular membrane protein excretion, which was related to both 5-ASA dose and disease activity. The 34 54 Although most case reports indicate reversibility after cessation of the drug, in some cases permanent clinical kidney dysfunction has been reported. 33 3 54 In all cases submitted to the pharmaceutical manufacturers36 acute renal damage was reported independent of dosage and treatment duration. Therefore, recent case reports may reflect acute allergic events rather than chronic toxicity. This hypothesis is supported by a case report in which rechallenge with both sulphasalazine and mesalazine drugs has been undertaken and in which a dose independent relapse of haematuria was found.37 The recent case reports of acute tubulointerstitial damage caused by aminosalicylates therefore most likely reflect a different pathophysiology than the findings reported in this study. The cases of acute renal failure associated with aminosalicylate therapy may describe a dose independent allergic condition, which may represent a clinical entity different from the findings reported in this study. Further prospective studies are warranted to dissect the potential influence of disease activity from 5-ASA treatment on renal tubular dysfunction. In particular the prospective evaluation of long term use of aminosalicylate drugs with different absorption kinetics (slow release mesalazine formulations (Pentasa), double molecules (olsalazinedipentum, SASP, balsalazide), and delayed release mesalazines (Salofalk, Claversal, Asacol)) may be of importance in dissecting the influence of a systemic load with 5-ASA from that of intestinal inflammation. Particular care should be taken in monitoring renal function indices (creatinine) in patients when further increasing long term 5-ASA dosages for treatment. However, at present no clinical data have been presented suggesting that chronic treatment with aminosalicylates is unsafe unless a hypersensitivity reaction occurs.
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